POLTREG
PolTREG’s four most advanced projects are already in the clinical stage of development in the areas of type 1 diabetes and multiple sclerosis. The portfolio also includes projects based on the next generation of genetically modified T-regulatory lymphocytes. The PolTREG team consists of experienced managers, biotechnology specialists and scientists. The founders have over 17 years of experience in the use of T-regulatory cells in the treatment of autoimmune diseases. The Company’s Scientific Advisory Board includes key world-class opinion leaders.
POLTREG
Founded:
2015-01-01
Address:
Gdansk, Pomorskie, Poland
Country:
Poland
Website Url:
http://www.poltreg.com
Total Employee:
101+
Status:
Active
Contact:
48 512 532 401
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress WordPress 6.4 COVID-19 WP Rocket WPML Multilingual
Similar Organizations
4Dcell
4Dcell is a biotechnology company.
Apis Assay Technologies
Apis Assay Technologies is a biotechnology company.
Corlieve Therapeutics
Corlieve Therapeutics is a biotechnology company.
EHT Technologies
EHT Technologies is a biotechnology company.
Evictas
Evictas is a biotechnology company.
GlasPort Bio
GlasPort Bio is a biotechnology company.
Laxxon Medical
Laxxon Medical is a biotechnology company.
Solaga
Biotechnology Company
Stemedica International
Stemedica International is a biotechnology company.
VemiCo
VemiCo is a biotechnology company.
Current Employees Featured
Key Employee Changes
| Date | New article |
|---|---|
| 2024-02-21 | PolTREG appoints Dan Shelly as Chief Business Development Officer |
Official Site Inspections
http://www.poltreg.com Semrush global rank: 3.11 M Semrush visits lastest month: 4.95 K
- Host name: d23.thecamels.org
- IP address: 185.135.90.56
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "PolTREG"
Poltreg – The future of medicine
PolTREG growth market Treg therapies offer vast commercial potential, with potential peak sales for PTG-007 estimated at $1.9 billion for newly diagnosed T1D. PolTREG S.A. Botaniczna 20, …See details»
About us - Poltreg
The PolTREG team consists of experienced managers, biotechnology specialists and scientists. The founders have over 17 years of experience in the use of T-regulatory cells in the treatment …See details»
Poltreg - Crunchbase Company Profile & Funding
PolTREG was established as a spin-off from the Medical University of GdaÅ„sk in order to develop and commercialize patented TREG method. Due to positive results of clinical trials of TREG …See details»
PolTREG - Crunchbase Company Profile & Funding
Organization. PolTREG . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. PolTREG is a biotechnology company. Gdansk, Pomorskie, …See details»
Poltreg S.A. Company Profile - Poland | Financials & Key …
Nov 12, 2024 PolTREG S.A. is a biotechnology company founded in 2015. The company is headquartered in Gdansk and has a Research and Development Center located there as well. …See details»
PolTREG - Company Profile - Tracxn
Oct 31, 2024 PolTREG ranks 114th among 243 active competitors. 94 of its competitors are funded while 51 have exited. Overall, PolTREG and its competitors have raised over $12.7B in …See details»
Poltreg S.A. - life-sciences-europe.com
Jan 1, 2015 PolTREG S.A. is a biotechnology company founded in 2015. The headquarters and its laboratories are located in Gdansk. The Company’s mission is to develop effective T …See details»
Poltreg Company Profile - Office Locations, Competitors ... - Craft
Poltreg has 5 employees across 2 locations and $55.52 k in total funding,. See insights on Poltreg including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Poltreg - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Poltreg . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 22. About. Poltreg is …See details»
PolTREG is expanding its cGMP capabilities, which are currently …
Jun 15, 2023 PolTREG S.A., a leader in cell therapies based on T-regulatory lymphocytes (TREG), is expanding its cGMP capabilities with the announcement of the completion of the …See details»
Poltreg Company Profile 2024: Stock Performance & Earnings
Poltreg has 31 total employees. What industry is Poltreg in? Poltreg’s primary industry is Biotechnology. Is Poltreg a private or public company? Poltreg is a Public company. What is …See details»
Poltreg - Overview, News & Similar companies | ZoomInfo.com
Feb 20, 2024 PolTREG appoints Dan Shelly as Chief Business Development Officer - BioSpace PolTREG S.A. announces it has appointed Prof. Daniel Shelly, PhD, MBA, into the role of …See details»
PolTREG
PolTREG’s main goal is the implementation of TREG method on the Polish as well as international market. Due to special character of the biotechnology sector (especially red …See details»
Poltreg - Crunchbase
Poltreg focuses on commercializing the TREG method from the Medical University of GdaÅ„sk. Semma Therapeutics and Excision BioTherapeutics are both dedicated to developing …See details»
PolTREG Receives US Patent Office Notice of Allowance for Treg …
Jan 16, 2024 PolTREG’s portfolio of patents and patent applications, in U.S. and Europe, includes the formulation of polyclonal and engineered Treg products, unique manufacturing …See details»
PolTREG receives US Patent Office Notice of Allowance for Treg …
Jan 16, 2024 PolTREG announces it has received a Notice of Allowance from the US Patent Office covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), …See details»
Poltreg - Updates, News, Events, Signals & Triggers - Crunchbase
Poltreg was established as a spin-off from the Medical University of GdaÅ„sk in order to develop and commercialize the patented TREG method. Search Crunchbase. Start Free Trial . Chrome …See details»
PolTREG’s state-of-the-art manufacturing facility has received …
Mar 11, 2024 PolTREG has more than 17 years of experience treating patients. We have administered Treg cells to more than 100 people over that period, either in hospital exemption …See details»
News & Media - Poltreg
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones. See. 2024-02-07. Global institutional …See details»
PolTREG completes next stage of state-of-the-art manufacturing …
Dec 29, 2023 PolTREG has just completed construction of the second phase of one of Europe’s most advanced cell and gene therapy manufacturing facilities, featuring: – 15 stand-alone …See details»